All in on nov­el tar­get GSK-3β, Ac­tu­ate Ther­a­peu­tics rais­es $21M+ to bankroll am­bi­tious PhI/II

As Ac­tu­ate Ther­a­peu­tics ramps up re­cruit­ment for what it calls a “ground­break­ing” Phase I/II in­volv­ing re­frac­to­ry blood can­cers and sol­id tu­mors, the biotech has se­cured …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.